Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

OREIOS International Study
OREIOS International Study

NCT05239507

CompletedN/A

Sponsor: AstraZeneca

Conditions: Hepatocellular Carcinoma

Countries: Brazil, Egypt, Hong Kong, India, Kuwait, Oman, Russia, Saudi Arabia

Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care. Based on all these considerations, this multicountry, multicentre, noninterventional, real-world, retrospective study is designed to describe the management patterns, clinical characteristics, possible predictors, and survival outcomes in patients with unresectable HCC. The results of this study might help oncologists in optimal patient selection and sequencing of the systemic therapies.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

1. Adult female or male patients aged ≥18 years or 'adults' according to the age of majority as defined by the local regulations at index diagnosis
2. Patients or legal representative (unless a waiver is granted) willing and be able to provide informed consent according to local regulations. For deceased patients at study entry, informed consent is not mandatory.
3. Patients with radiologically or histopathologically confirmed diagnosis (at index date) of unresectable BCLC stage B HCC, not considered eligible for initial loco-regional therapya or stage C advanced or metastatic disease, between 01 January 2017 and 31 December 2019.
4. Availability of at least 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis.

Exclusion Criteria:

1. Patients with BCLC stage D HCC at index diagnosis
2. Patients with concomitant cancer, at the time of diagnosis of unresectable HCC, except for the nonmetastatic nonmelanoma skin cancers or in situ or benign neoplasms; a cancer is considered concomitant if it occurs within 5 years of HCC diagnosis.
Locations (21)
  • Porto Alegre, Rio Grande do Sul, Brazil
  • São Paulo, Brazil
  • Alexandira, Egypt
  • Asyut, Egypt
  • Cairo, Egypt
  • Menufia, Egypt
  • Hong Kong, Hong Kong
  • Faridabad, India
  • Howrah, India
  • Kolkata, India
  • New Delhi, India
  • Kuwait City, Kuwait
  • Muscat, Oman
  • Chelyabinsk, Russia
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Mecca, Saudi Arabia
  • Riyadh, Saudi Arabia
  • Singapore, Singapore
  • Seoul, South Korea
  • Abu Dhabi, United Arab Emirates